MNKD → $10.00 by Aug 18, 2026.

$MNKD currently has 2 products with excellent chances of FDA approval in May & July this year 1. FUROSCIX ReadyFlow Autoinjector PDUFA: July 26, 2026 2. Afrezza Pediatric Indication PDUFA: May 29, 2026 The stock took a major drop in February when it's partner United Therapeutics announced it was developing it's own competitor drug for Mannkind's bestseller Tyvaso, but this product won't be ready for a market launch until 2028 (and that's only if everything goes smoothly) so the drop …